FRANKFURT: BioNTech said Singapore’s Temasek and other investors are injecting US$250mil into the German biotech firm through a private placement, reflecting heightened investor appetite for promising developers’ vaccines against the coronavirus.
The company, which went public on the US Nasdaq in October last year, said the investors would purchase about US$139mil in ordinary shares and US$112mil in four-year mandatory convertible notes.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!